HK1203967A1 - 神經節苷脂生產的方法 - Google Patents

神經節苷脂生產的方法

Info

Publication number
HK1203967A1
HK1203967A1 HK15104440.1A HK15104440A HK1203967A1 HK 1203967 A1 HK1203967 A1 HK 1203967A1 HK 15104440 A HK15104440 A HK 15104440A HK 1203967 A1 HK1203967 A1 HK 1203967A1
Authority
HK
Hong Kong
Prior art keywords
methods
ganglioside production
ganglioside
production
Prior art date
Application number
HK15104440.1A
Other languages
English (en)
Inventor
Vanessa Ragaglia
Vandana Sharma
Original Assignee
Garnet Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Garnet Biotherapeutics Inc filed Critical Garnet Biotherapeutics Inc
Publication of HK1203967A1 publication Critical patent/HK1203967A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
HK15104440.1A 2012-01-20 2015-05-11 神經節苷脂生產的方法 HK1203967A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261588882P 2012-01-20 2012-01-20
PCT/US2013/022201 WO2013109929A1 (en) 2012-01-20 2013-01-18 Methods of ganglioside production

Publications (1)

Publication Number Publication Date
HK1203967A1 true HK1203967A1 (zh) 2015-11-06

Family

ID=48797708

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104440.1A HK1203967A1 (zh) 2012-01-20 2015-05-11 神經節苷脂生產的方法

Country Status (14)

Country Link
US (4) US9556467B2 (zh)
EP (1) EP2804871B1 (zh)
JP (1) JP2015511120A (zh)
KR (1) KR102039204B1 (zh)
CA (1) CA2862157C (zh)
DK (1) DK2804871T3 (zh)
ES (1) ES2634387T3 (zh)
HK (1) HK1203967A1 (zh)
IL (1) IL233664A0 (zh)
MX (1) MX2014008797A (zh)
NZ (1) NZ626767A (zh)
SG (1) SG11201404236SA (zh)
WO (1) WO2013109929A1 (zh)
ZA (1) ZA201405321B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2581523T3 (es) 2009-09-01 2016-09-06 Lz Therapeutics, Inc. Producción en cultivo celular (no bovino, no porcino) de GM1
US9556467B2 (en) 2012-01-20 2017-01-31 Garnet Bio Therapeutics, Inc. Methods of ganglioside production
AU2014233521A1 (en) * 2013-03-15 2015-08-20 Garnet Biotherapeutics, Inc. Ganglioside compositions
EP3012321B1 (en) * 2014-09-05 2019-04-03 Korea Research Institute of Bioscience and Biotechnology Human cell model of gm1 gangliosidosis and use of same
US11554130B2 (en) 2019-01-11 2023-01-17 GlycoScience Research, Inc. Treatment of neurodegenerative disease with ovine GM1 gangliosidosis GM1 ganglioside

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1199116B (it) 1984-07-03 1988-12-30 Fidia Farmaceutici Derivati di gangliosidi
JP2724588B2 (ja) 1988-05-02 1998-03-09 丸金醤油株式会社 ノイラミニダーゼ・アイソザイムｓ及びガングリオシド類の製造法
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
CU22420A1 (es) 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
JP3615798B2 (ja) 1994-09-30 2005-02-02 雪印乳業株式会社 ガングリオシドの製造法
US5635504A (en) 1995-06-07 1997-06-03 Bristol-Myers Squibb Co. Diazepine containing dual action inhibitors
US5532141A (en) 1995-06-13 1996-07-02 Holler; Larry D. Process for obtaining ganglioside lipids
AU718171B2 (en) 1996-07-19 2000-04-06 Takara Bio Inc. Methods for producing sphingolipids and sphingolipid derivatives
US6410046B1 (en) 1996-11-19 2002-06-25 Intrabrain International Nv Administering pharmaceuticals to the mammalian central nervous system
US6555371B1 (en) 1997-07-09 2003-04-29 Seikagaku Kogyo Kabushiki Kaisha Sialyltransferase and DNA encoding the same
WO1999028491A1 (en) 1997-12-01 1999-06-10 Cytel Corporation Enzymatic synthesis of gangliosides
CN1353112A (zh) 2000-11-09 2002-06-12 重庆富进生物医药有限公司 单唾液酸四己糖神经节苷脂的高纯度制备工艺
JP4681226B2 (ja) 2001-12-21 2011-05-11 ビスカム・アーゲー ヤドリギレクチンに対する個体の応答性を判定する方法
IL154318A (en) 2003-02-06 2010-05-31 Sarah Herzog Memorial Hospital Pharmaceutical compositions for the treatment of movement disorders
WO2004083387A2 (en) 2003-03-13 2004-09-30 Corixa Corporation Anti-ganglioside antibodies and methods of use
US7851451B2 (en) 2004-03-12 2010-12-14 Mti Meta Tech Inc. Formulations for mediating inflammatory bowel disorders
KR20070007908A (ko) 2004-05-07 2007-01-16 메르크 파텐트 게엠베하 당뇨병의 미세혈관 합병증의 치료 표적으로서의 ｇｍ３신타제
CA2585471A1 (en) 2004-11-01 2006-05-11 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
US20100048653A1 (en) 2005-07-14 2010-02-25 The University Of British Columbia Neuroprotective modulation of nmda receptor subtype activities
IL172175A0 (en) 2005-11-24 2011-08-01 Hadasit Med Res Service Beta glycolipids as immuno-modulators
WO2008033754A2 (en) 2006-09-11 2008-03-20 Duke University Xanthine derivatives in methods and compositions for the treatment of vascular depression
EP1902733A1 (en) 2006-09-19 2008-03-26 Laboratorios Del Dr. Esteve, S.A. Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
US7943750B2 (en) 2007-06-18 2011-05-17 Laboratoire Medidom S.A. Process for obtaining pure monosialoganglioside GM1 for medical use
CA2772877A1 (en) 2009-09-01 2011-03-10 Lz Therapeutics, Inc. Treatment of glaucoma and other retinopathies with gangliosides
EP2473174A4 (en) 2009-09-01 2014-02-26 Lz Therapeutics Inc TRANSMUCOSAL GANGLIOSIDE FORMULATIONS
ES2581523T3 (es) * 2009-09-01 2016-09-06 Lz Therapeutics, Inc. Producción en cultivo celular (no bovino, no porcino) de GM1
US9556467B2 (en) 2012-01-20 2017-01-31 Garnet Bio Therapeutics, Inc. Methods of ganglioside production
AU2014233521A1 (en) 2013-03-15 2015-08-20 Garnet Biotherapeutics, Inc. Ganglioside compositions

Also Published As

Publication number Publication date
WO2013109929A1 (en) 2013-07-25
EP2804871A4 (en) 2015-09-02
MX2014008797A (es) 2014-10-30
US20170101657A1 (en) 2017-04-13
NZ626767A (en) 2016-11-25
US20130190257A1 (en) 2013-07-25
CA2862157A1 (en) 2013-07-25
SG11201404236SA (en) 2014-11-27
US9051592B2 (en) 2015-06-09
ZA201405321B (en) 2022-05-25
JP2015511120A (ja) 2015-04-16
EP2804871B1 (en) 2017-04-12
ES2634387T3 (es) 2017-09-27
CA2862157C (en) 2016-03-22
US9556467B2 (en) 2017-01-31
KR20150035485A (ko) 2015-04-06
EP2804871A1 (en) 2014-11-26
US20130261067A1 (en) 2013-10-03
US20220073959A1 (en) 2022-03-10
IL233664A0 (en) 2014-08-31
KR102039204B1 (ko) 2019-10-31
DK2804871T3 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
HUE037048T2 (hu) Eljárások 4-cikloalkiloxibenzolszulfonamidok elõállítására
LT3225604T (lt) Daugiasluoksnių lango stiklų gamybos būdas
SG11201405573WA (en) Production of graphene
HUE057406T2 (hu) Készülék technécium-99M ciklotronos elõállítására
EP2913831A4 (en) PROCESS FOR PRODUCING RARE EARTH MAGNET
ZA201406494B (en) Methods of producing sulfilimine compounds
EP2937328A4 (en) PROCESS FOR PRODUCING ALCOHOL
SG11201405572QA (en) Process for producing polydienes
ZA201502519B (en) Production of particles
PL2836460T3 (pl) Sposób wytwarzania grafenu
HK1207112A1 (zh) 代謝途徑產物的生成方法
PL2931937T3 (pl) Sposób wytwarzania układów nanocząstek metali
HK1205097A1 (zh) 用於生產甲基丁炔醇的方法
EP2935300A4 (en) NEW POLYMORPHS FROM LNNT
HK1203967A1 (zh) 神經節苷脂生產的方法
GB201220155D0 (en) Method of manufacture
IL237862A0 (en) Methods to reduce the formation of scale
SI2828396T1 (sl) Postopek za pripravo G-CSF
HK1214601A1 (zh) 用於製造 -標記物的新型雙-銥-配合物
HK1210225A1 (zh) 生產台勾霉素 的流程
EP2826805A4 (en) PROCESS FOR THE PRODUCTION OF CONTINUOUS POLYCARBONATE
EP2855401A4 (en) PREPARATION OF BN COMPOUNDS
EP2832696A4 (en) MAYENITHERSTELLUNGSVERFAHREN
GB201215942D0 (en) Method of treatent
EP2887938A4 (en) PROCESS FOR PREPARING TECOVIRIMAT